Alejandro A, Baraldés-Rovira M, Gallego Y, et al. - This research was sought to ascertain the willingness of candidate patients to change their treatment and to monitor the evolution of their attitude. Researchers distinguished patients aged between 15 and 45 years old who had been diagnosed with epilepsy and were being treated with valproic acid (VPA). They recorded a shared decision-making visit was arranged, during which variables related to their epilepsy. This analysis enrolled a sum of 60 patients, with a median age of 32.7 years. A significant number of individuals and legal guardians opted to continue with this treatment; the reasons given for this were the low possibility of pregnancy and the risk of breakthrough seizures. This study's findings demonstrate that in almost half, the cases studied, despite being informed of the teratogenic risk correlated with VPA, the pharmacological alternatives to VPA were poorly tolerated and did not serve a good level of seizure control.